Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hemophilia

Take a walk on the wild side!

The Say Comms team are raising money for The Haemophilia Society with a walk-a-thon sponsor them here http://bit.ly/1MtvDO8

Say Communications

Bayer symbol

Bayer gets first approval for Kogenate upgrade Kovaltry

First worldwide licence for the haemophilia treatment

- PMLiVE

Novo Nordisk files improved haemophilia B therapy in EU

Nonacog beta pegol is due to be submitted to US regulators in the next few months

Biogen Idec building

Biogen and Sobi’s Elocta wins EU approval

First haemophilia A treatment to offer prolonged protection against bleeding

- PMLiVE

BPL bags FDA approval for rare bleeding disorder therapy

First drug approved for hereditary Factor X deficiency

Novo launches online news channel for haemophilia patients

New medical information website aims to be a 'simple, centralised repository'

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

- PMLiVE

Tantalising data for Baxter spin-off’s haemophilia therapy

Early-stage testing shows promise as a potentially transformative treatment

- PMLiVE

Sobi launches disease awareness app with UK hospital

Pharma firm links with GOSH on helping children with haemophilia

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

- PMLiVE

Baxter haemophilia drug clears phase III trial

BAX 817 shown to resolve more than 90% of acute bleeds

Pharma’s pigeons

If it can adapt, a lucrative new niche is opening up for pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links